Healthcare CFOs are not taking over AI governance, but they are becoming the economic gatekeepers for which AI investments are funded, scaled, renewed, or stopped. The CFO's immediate challenge is that most organizations cannot yet connect AI spending to attributable financial, clinical, and operational outcomes using evidence strong enough for executive or board scrutiny. Finance can evaluate capital efficiency, but it cannot independently determine whether an AI system is clinically appropriate, technically reliable, secure, operationally sustainable, or legally defensible. The institution needs a shared evidence and accountability structure, one accountable owner per investment, and explicit decision rules for scaling, correcting, suspending, or terminating the system.
What is changing
AI is moving out of experimentation and into enterprise operations. As spending and institutional dependence grow, enthusiasm and adoption metrics are no longer sufficient. CFOs are increasingly expected to answer:
- What are we spending across the entire AI portfolio?
- Which outcomes can be attributed to each investment?
- What financial, clinical, operational, cybersecurity, and liability exposures accompany those returns?
- Who is accountable when results deteriorate or controls fail?
- What evidence supports continuing, expanding, or terminating the investment?
The management gap
Finance can evaluate capital efficiency, but it cannot independently determine whether an AI system is clinically appropriate, technically reliable, secure, operationally sustainable, or legally defensible.
The institution therefore needs a shared evidence and accountability structure across:
- Finance and capital allocation
- Clinical quality and patient safety
- Technology and cybersecurity
- Operations and workforce
- Legal, compliance, and privacy
- Executive and board oversight
Without this structure, the CFO receives fragmented claims from different functions and remains unable to evaluate the investment as one enterprise decision.
What evidence should a CFO require before AI is funded, scaled, renewed, or stopped?
- Defined value thesis: the specific financial or operational outcome expected and how it will be measured.
- Attribution method: evidence separating the AI system's contribution from unrelated changes.
- Total cost of ownership: technology, integration, infrastructure, security, monitoring, workflow redesign, training, governance, and remediation costs.
- Clinical and operational thresholds: predefined safety, quality, reliability, and workflow requirements.
- Named accountable owner: one executive responsible for the total outcome, not merely the technology or implementation.
- Ongoing evidence: production performance, control effectiveness, incidents, exceptions, and value realization.
- Decision rules: explicit thresholds for scaling, correcting, suspending, or terminating the system.
Recommended CFO action
Establish centralized AI portfolio reporting that brings financial value, clinical outcomes, operational performance, technical reliability, cybersecurity, and governance evidence into the same decision process.
Require joint finance and operational approval at four gates:
- Initial funding
- Production deployment
- Expansion or renewal
- Continuation or termination
The board-level question: can management demonstrate, with defensible evidence, that each material AI investment is producing attributable value within acceptable clinical, operational, cybersecurity, legal, and financial exposure?
The role of the Trustworthy Technology & Innovation Consortium
The Trustworthy Technology & Innovation Consortium (TTIC) equips finance leaders to participate in trustworthy AI decisions without positioning finance as a substitute for clinical, technical, or operational leadership. The work is to define the evidence requirements, decision rights, escalation paths, and cross-functional accountability needed to govern AI as an institutional asset and liability.
Sherri Douville
Founder & Chair, Trustworthy Technology & Innovation Consortium